产品
编 号：F080159
分子式：C10H18O4
分子量：202.25
分子式：C10H18O4
分子量：202.25
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 122110-53-6
产品详情
生物活性：
Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties.
体内研究：
Pivanex (AN9, 200 mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss.Animal Model:SMN7 SMA mice (SMN2+/+; SMN7+/+; mSmn?/?).
Dosage:200 mg/kg.
Administration:Oral administration, b.i.d, at 09.00 and 17.00 daily.
Result:Improved the mean lifespan of treated SMN7 SMA mice by 84.6%.Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.
体外研究：
Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells.Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells.Pivanex (200 μM)induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle.Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties.
体内研究：
Pivanex (AN9, 200 mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss.Animal Model:SMN7 SMA mice (SMN2+/+; SMN7+/+; mSmn?/?).
Dosage:200 mg/kg.
Administration:Oral administration, b.i.d, at 09.00 and 17.00 daily.
Result:Improved the mean lifespan of treated SMN7 SMA mice by 84.6%.Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.
体外研究：
Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells.Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells.Pivanex (200 μM)induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle.Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备